One is an oncolytic vaccinia virus armed with a superagonist IL-15 (IL-15-IL-15Rα fusion) given alone or in combination with anti-PD-1: combined treatment demonstrated T cell-driven anti-tumor efficacy in in vivo mouse models of cancer (126). Here, PDCD1 is linked to neoplasm.